Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Free Cash Flow: 2012-2024

Historic Free Cash Flow for Rocket Pharmaceuticals (RCKT) over the last 13 years, with Dec 2024 value amounting to -$215.6 million.

  • Rocket Pharmaceuticals' Free Cash Flow rose 6.19% to -$50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.8 million, marking a year-over-year decrease of 0.23%. This contributed to the annual value of -$215.6 million for FY2024, which is 2.00% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Free Cash Flow stood at -$215.6 million for FY2024, which was down 2.00% from -$211.4 million recorded in FY2023.
  • Rocket Pharmaceuticals' 5-year Free Cash Flow high stood at -$95.2 million for FY2020, and its period low was -$215.6 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$211.4 million (2023), whereas its average is -$204.5 million.
  • Data for Rocket Pharmaceuticals' Free Cash Flow shows a maximum YoY tumbled of 44.82% (in 2022) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Free Cash Flow (Yearly) stood at -$95.2 million in 2020, then slumped by 35.21% to -$128.8 million in 2021, then slumped by 44.82% to -$186.5 million in 2022, then declined by 13.33% to -$211.4 million in 2023, then decreased by 2.00% to -$215.6 million in 2024.